Paraoxonase-1 inhibits oxidized low-density lipoprotein-induced metabolic alterations and apoptosis in endothelial cells: A nondirected metabolomic study

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  García Heredia, Anabel ^a   Marsillach, Judit ^b   Rull, Anna ^a   Triguero, Iris ^a   Fort, Isabel ^a,c   MacKness, Bharti ^a   MacKness, Michael ^a   Shih, Diana M ^d   Joven, Jorge ^a   Camps, Jordi ^a  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Laboratori de Referència Sud   (Spain)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; ARYLDIALKYLPHOSPHATASE; CASPASE 9; PHOSPHOLIPID;

APOPTOSIS; ARTICLE; CARBOHYDRATE METABOLISM; CELL SURVIVAL; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; METABOLISM; METABOLOMICS; MOUSE; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; CITRIC ACID CYCLE; FLOW CYTOMETRY; GENETICS; GLYCOLYSIS; MUTANT MOUSE STRAIN; PHYSIOLOGY;

MUS;

ANIMALS; APOPTOSIS; ARYLDIALKYLPHOSPHATASE; CASPASE 9; CITRIC ACID CYCLE; ENDOTHELIAL CELLS; FLOW CYTOMETRY; GLYCOLYSIS; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; PHOSPHOLIPIDS;

EID: 84878645452     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/156053     Document Type: Article

References (32)

1. Ross R., Atherosclerosis-an inflammatory disease. New England Journal of Medicine 1999 340 2 115 126 2-s2.0-0033552883 10.1056/NEJM199901143400207 (Pubitemid 29054847)
2. Profumo E., Buttari B., Petrone L., Redox imbalance of red blood cells impacts T lymphocyte homeostasis: implication in carotid atherosclerosis. Thrombosis and Haemostasis 2011 106 6 1117 1126 10.1160/TH11-02-0110
3. Liu T. F., Brown C. M., El Gazzar M., Fueling the flame: bioenergy couples metabolism and inflammation. Journal of Leukocyte Biology 2012 92 3 49 507
4. Berliner J., Lipid oxidation products and atherosclerosis. Vascular Pharmacology 2002 38 4 187 191 2-s2.0-0036549988 10.1016/S1537-1891(02)00168-4 (Pubitemid 36398264)
5. Madamanchi N. R., Vendrov A., Runge M. S., Oxidative stress and vascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology 2005 25 1 29 38 2-s2.0-11144225245 10.1161/01.ATV.0000150649.39934.13 (Pubitemid 40054251)
6. Aviram M., Rosenblat M., Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radical Biology and Medicine 2004 37 9 1304 1316 2-s2.0-5344238178 10.1016/j. freeradbiomed.2004.06.030 (Pubitemid 39349234)
7. Camps J., Marsillach J., Joven J., The paraoxonases: role in human diseases and methodological difficulties in measurement. Critical Reviews in Clinical Laboratory Sciences 2009 46 2 83 106 2-s2.0-61449118867 10.1080/10408360802610878
8. Khersonsky O., Tawfik D. S., Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 2005 44 16 6371 6382 2-s2.0-17644367506 10.1021/bi047440d (Pubitemid 40570731)
9. Marsillach J., Camps J., Beltran-Debón R., Rull A., Aragones G., Maestre-Martínez C., Sabench F., Hernández M., Castillo D. D., Joven J., Mackness M., Mackness B., Immunohistochemical analysis of paraoxonases-1 and 3 in human atheromatous plaques. European Journal of Clinical Investigation 2011 41 3 308 314 2-s2.0-79551664540 10.1111/j.1365-2362.2010. 02411.x
10. Shih D. M., Gu L., Xia Y. R., Navab M., Li W. F., Hama S., Castellani L. W., Furlong C. E., Costa L. G., Fogelman A. M., Lusis A. J., Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998 394 6690 284 287 2-s2.0-0032537833 10.1038/28406 (Pubitemid 28335041)
11. Mackness B., Hine D., Liu Y., Mastorikou M., Mackness M., Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochemical and Biophysical Research Communications 2004 318 3 680 683 2-s2.0-2442575983 10.1016/j.bbrc.2004.04.056 (Pubitemid 38624207)
12. Mackness M. I., Durrington P. N., Converse C. A., Skinner E. R., Lipoprotein analysis for clinical studies. Lipoprotein Analysis: A Practical Approach 1992 Oxford, UK IRL Press 1 42
13. Marsillach J., Aragones G., Mackness B., Mackness M., Rull A., Beltran-Debon R., Pedro-Botet J., Alonso-Villaverde C., Joven J., Camps J., Decreased paraoxonase-1 activity is associated with alterations of high-density lipoprotein particles in chronic liver impairment. Lipids in Health and Disease 2010 9 46 2-s2.0-77952048387 10.1186/1476-511X-9-46
14. Weiner J. III, Parida S. K., Maertzdorf J., Biomarkers of inflammation, immunosuppression and stress with active disease are revealed by metabolomic profiling of tuberculosis patients. PLoS One 2012 7 7 e40221
15. Ohisson B. G., Englund M. C. O., Karlsson A. L. K., Knutsen E., Erixon C., Skribeck H., Liu Y., Bondjers G., Wiklund O., Oxidized low density lipoprotein inhibits lipopolysaccharide-induced binding of nuclear factor- B to DNA and the subsequent expression of tumor necrosis factor- α and interleukin-1 β in macrophages. Journal of Clinical Investigation 1996 98 1 78 89 2-s2.0-0030056027 (Pubitemid 26243823)
16. Marsillach J., Aragonès G., Beltrán R., Caballeria J., Pedro-Botet J., Morcillo-Suárez C., Navarro A., Joven J., Camps J., The measurement of the lactonase activity of paraoxonase-1 in the clinical evaluation of patients with chronic liver impairment. Clinical Biochemistry 2009 42 1-2 91 98 2-s2.0-57649087483 10.1016/j.clinbiochem.2008.09.120
17. Pacher P., Szabó C., Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme. Antioxidants and Redox Signaling 2005 7 11-12 1568 1580 2-s2.0-28844462418 10.1089/ars.2005.7.1568 (Pubitemid 41767992)
18. Widlansky M. E., Gutterman D. D., Regulation of endothelial function by mitochondrial reactive oxygen species. Antioxidants and Redox Signaling 2011 15 6 1517 1530 2-s2.0-79955753583 10.1089/ars.2010.3642
19. Asicioglu E., Yavuz D. G., Koc M., Ozben B., Yazici D., Deyneli O., Akalin S., Circulating endothelial cells are elevated in patients with type 1 diabetes mellitus. European Journal of Endocrinology 2010 162 4 711 717 2-s2.0-77950334145 10.1530/EJE-09-0795
20. Rozenberg O., Shiner M., Aviram M., Hayek T., Paraoxonase 1 (PON1) attenuates diabetes development in mice through its antioxidative properties. Free Radical Biology and Medicine 2008 44 11 1951 1959 2-s2.0-43049162677 10.1016/j.freeradbiomed.2008.02.012
21. Koren-Gluzer M., Aviram M., Meilin E., Hayek T., The antioxidant HDL-associated paraoxonase-1 (PON1) attenuates diabetes development and stimulates β -cell insulin release. Atherosclerosis 2011 219 2 510 518 10.1016/j.atherosclerosis.2011.07.119
22. Reubold T. F., Eschenburg S., A molecular view on signal transduction by the apoptosome. Cell Signaling 2012 24 7 1420 1425 10.1016/j.cellsig.2012.03.007
23. Besler C., Heinrich K., Rohrer L., Doerries C., Riwanto M., Shih D. M., Chroni A., Yonekawa K., Stein S., Schaefer N., Mueller M., Akhmedov A., Daniil G., Manes C., Templin C., Wyss C., Maier W., Tanner F. C., Matter C. M., Corti R., Furlong C., Lusis A. J., Von Eckardstein A., Fogelman A. M., Lüscher T. F., Landmesser U., Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. Journal of Clinical Investigation 2011 121 7 2693 2708 2-s2.0-79959919890 10.1172/JCI42946
24. Liu M. L., Scalia R., Mehta J. L., Williams K. J., Cholesterol-induced membrane microvesicles as novel carriers of damage-associated molecular patterns: mechanisms of formation, action, and detoxification. Arteriosclerosis Thrombosis and Vascular Biology 2012 32 9 2113 2121 10.1161/ATVBAHA.112.255471
25. Riwanto M., Rohrer L., Roschitzki B., Altered activation of endothelial anti- and pro-apoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of HDL-proteome remodeling. Circulation 2013 127 8 891 904 10.1161/CIRCULATIONAHA.112.108753
26. Joza N., Oudit G. Y., Brown D., Bénit P., Kassiri Z., Vahsen N., Benoit L., Patel M. M., Nowikovsky K., Vassault A., Backx P. H., Wada T., Kroemer G., Rustin P., Penninger J. M., Muscle-specific loss of apoptosis-inducing factor leads to mitochondrial dysfunction, skeletal muscle atrophy, and dilated cardiomyopathy. Molecular and Cellular Biology 2005 25 23 10261 10272 2-s2.0-27944475065 10.1128/MCB.25.23.10261-10272.2005 (Pubitemid 41681953)
27. Mackness M. I., Durrington P. N., Ayub A., Mackness B., Low serum paraoxonase: a risk factor for atherosclerotic disease? Chemico-Biological Interactions 1999 119-120 389 397 2-s2.0-0033039311 10.1016/S0009-2797(99)00050- 2 (Pubitemid 29278575)
28. Marsillach J., Camps J., Ferré N., Beltran R., Rull A., Mackness B., Mackness M., Joven J., Paraoxonase-1 is related to inflammation, fibrosis and PPAR delta in experimental liver disease. BMC Gastroenterology 2009 9 3 2-s2.0-61349170673 10.1186/1471-230X-9-3
29. Loued S., Isabelle M., Berrougui H., Khalil A., The anti-inflammatory effect of paraoxonase 1 against oxidized lipids depends on its association with high density lipoproteins. Life Sciences 2012 90 1-2 82 88 10.1016/j.lfs.2011. 10.018
30. Rosenblat M., Volkova N., Aviram M., Injection of paraoxonase 1 (PON1) to mice stimulates their HDL and macrophage antiatherogenicity. Biofactors 2011 37 6 462 467 10.1002/biof.188
31. Aharoni S., Aviram M., Fuhrman B., Paraoxonase 1 (PON1) reduces macrophage inflammatory responses. Atherosclerosis 2013 10.1016/j. atherosclerosis.2013.03.005
32. Hine D., Mackness B., Mackness M., Coincubation of PON1, APO A1, and LCAT increases the time HDL is able to prevent LDL oxidation. IUBMB Life 2012 64 2 157 161 10.1002/iub.588